Japanese scientists at the Tokyo Institute of Medical Sciences are developing a vaccine against coronavirus that can provide lifelong immunity. Clinical trials are expected to take place in 2023, according to The Japan Times.
Researchers say they took the smallpox vaccine, developed in the 18th century by Edward Jenner, as a basis. According to experts led by Professor Mitinori Kohara, it uses the cowpox virus, which is harmless to humans.
The idea is to create a recombinant smallpox virus that contains the coronavirus protein. It is thought that this should lead to the lifelong development of cellular immunity in the body.
Experiments on mice have shown that animals vaccinated with the vaccine were able to survive even after being infected with bird flu.
"I have worked on various vaccine technologies such as adenovirus and RNA vaccines, but the preparations that use the vector of smallpox virus in cows are the most powerful of all," Kohara said.
It is known in advance that the Japanese manufacturer Nobelpharma intends to conduct the first and second phases of clinical trials in 2023. The study will involve 150-200 people, including those who have suffered from Covid-19 and vaccinated against it. If the effectiveness of the drug is proven, they intend to put it on the market in 2024.
No comments:
Post a Comment